Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Colorectal Cancer Pipeline Products Market Report Overview
Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment includes surgery, radiation therapy, and chemotherapy.
The Colorectal cancer pipeline market research report provides comprehensive information on the therapeutics under development for colorectal cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.
| Key Targets | · Programmed Cell Death Protein 1
· GTPase KRas · Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 · Epidermal Growth Factor Receptor · Programmed Cell Death 1 Ligand 1 |
| Key Mechanisms of Action | · Programmed Cell Death Protein 1 Antagonist
· GTPase KRas Inhibitor · Cytotoxic To Cells Expressing · Receptor Tyrosine Protein Kinase ERBB 2 · Programmed Cell Death 1 Ligand 1 Inhibitor · DNA Topoisomerase I Inhibitor |
| Key Routes of Administration | · Intravenous
· Oral · Parenteral · Subcutaneous |
| Key Molecule Type | · Small Molecule
· Monoclonal Antibody · Gene-Modified Cell Therapy · Monoclonal Antibody Conjugated |
| Leading Companies | · Novartis AG
· AstraZeneca Plc · Bristol-Myers Squibb Co · Merck & Co Inc |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Colorectal Cancer Pipeline Products Market - Competitive Landscape
A few of the leading companies in the Colorectal Cancer pipeline products market are Novartis AG, AstraZeneca Plc, Bristol-Myers Squibb Co, Merck & Co. Inc, Pfizer Inc, Boehringer Ingelheim International GmbH, CSPC Pharmaceutical Group Ltd, BeiGene Ltd, Jacobio Pharmaceuticals Group Co Ltd, and Johnson & Johnson. Novartis AG was the leading company with the highest number of products in the Colorectal Cancer pipeline products market.
Novartis AG: Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture, and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR).
Colorectal Cancer Pipeline Products Market Analysis by Companies, 2022 (%)
Buy the Full Report To know more about the leading players in the Colorectal Cancer Pipeline Products Market, Download a Free Report Sample
Colorectal Cancer Pipeline Products Market Segmentation by Targets
The key targets in the Colorectal Cancer pipeline products market are Programmed Cell Death Protein 1, GTPase KRas, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Epidermal Growth Factor Receptor, and Programmed Cell Death 1 Ligand 1, among others. Programmed Cell Death Protein 1 was the leading target in the pipeline.
Colorectal Cancer Pipeline Products Market Analysis by Targets, 2022 (%)
Buy the Full Report for More Target Insights into the Colorectal Cancer Pipeline Products Market, Download a Free Report Sample
Colorectal Cancer Pipeline Products Market Segmentation by Mechanisms of Action
A few of the key mechanisms of action in the Colorectal Cancer pipeline products market are Programmed Cell Death Protein 1 Antagonist, GTPase KRas Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, and Programmed Cell Death 1 Ligand 1 Inhibitor, among others. Programmed Cell Death Protein 1 Antagonist was the leading MoA in the pipeline market in 2022.
Colorectal Cancer Pipeline Products Market Analysis by Mechanisms of Action, 2022 (%)
Buy the Full Report for More Mechanisms of Action Insights into the Colorectal Cancer pipeline Products Market, Download a Free Report Sample
Colorectal Cancer Pipeline Products Market Segmentation by Routes of Administration
A few of the key routes of administration in the Colorectal Cancer pipeline products market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, intramuscular, intradermal, topical, and intraperitoneal, among others. Intravenous was the most preferred route for administration in 2022.
Colorectal Cancer Pipeline Products Market Analysis by Routes of Administration, 2022 (%)
Buy the Full Report for More Routes of Administration Insights into the Colorectal Cancer Pipeline Products Market, Download a Free Report Sample
Colorectal Cancer Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Colorectal Cancer pipeline products market are small molecule, monoclonal antibody, gene-modified cell therapy, monoclonal antibody conjugated, fusion protein, cell therapy, oncolytic virus, subunit vaccine, biologic, and synthetic peptide, among others. The leading molecule type was a small molecule in 2022.
Colorectal Cancer Pipeline Products Market Analysis by Molecule Types, 2022 (%)
Buy the Full Report for More Molecule Type Insights into the Colorectal Cancer Pipeline Products Market, Download a Free Report Sample
Colorectal Cancer Pipeline Products Market – Featured News and Press Releases
- On Dec 06, 2022, Kineta to participate in JMP Securities Hematology and Oncology Summit
- On Dec 01, 2022, Pyxis Oncology announced IND clearance from the FDA for PYX-106
Buy the Full Report for More Routes of Administration Insights into the Colorectal Cancer Pipeline Products Market, Download a Free Report Sample
Key Segments Covered in this Report
Colorectal Cancer Pipeline Products Target Outlook (2022)
- Programmed Cell Death Protein 1
- GTPase KRas
- Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2
- Epidermal Growth Factor Receptor
- Others
Colorectal Cancer Pipeline Products MoA Outlook (2022)
- Programmed Cell Death Protein 1 Antagonist
- GTPase KRas Inhibitor
- Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2
- Programmed Cell Death 1 Ligand 1 Inhibitor
- Others
Colorectal Cancer Pipeline Products RoA Outlook (2022)
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Others
Colorectal Cancer Pipeline Products Molecule Type Outlook (2022)
- Small Molecule
- Monoclonal Antibody
- Gene-Modified Cell Therapy
- Monoclonal Antibody Conjugated
- Others
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Colorectal Cancer (Oncology).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
3SBio Inc
4D Pharma Plc
4SC AG
A2 Biotherapeutics Inc
AB Pharma Ltd
AbbVie Inc
Abclon Inc
Abcuro Inc
ABL Bio Inc
ABM Therapeutics Inc
Abtlas
AC Bioscience SA
AcadeMab Biomedical Inc
Aclaris Therapeutics Inc
Adagene Suzhou Ltd
Adamed Pharma SA
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
ADT Pharmaceuticals Inc
Advanced Accelerator Applications SA
Advanced BioDesign
Advaxis Inc
Advenchen Laboratories LLC
Affimed GmbH
Agenus Inc
Agilvax Inc
AI Therapeutics Inc
Aileron Therapeutics Inc
AilseVax Ltd
Akeso Inc
Aktis Oncology Inc
Alfasigma SpA
Alkermes Plc
Alligator Bioscience AB
Allinky Biopharma SL
Allist Shanghai Pharmaceutical Technology Co Ltd
Almac Discovery Ltd
AlphaMab Co Ltd
Alphamab Oncology
AlphaVax Inc
Alpine Immune Sciences Inc
Altamira Therapeutics Ltd
Altimmune Inc
AltruBio Inc
Amarin Corp Plc
Ambrx Biopharma Inc
amcure GmbH
Amgen Inc
Amitech Therapeutic Solutions Inc
AmMax Bio Inc
Amphivena Therapeutics Inc
Amrita Therapeutics
Amunix Operating Inc
Anaveon AG
Andes Biotechnologies
Angex Pharmaceutical Inc
AnHeart Therapeutics Inc
Anhorn Medicines Co Ltd
Ansun Biopharma Inc
Apcegen Technologies Pvt Ltd
Apexian Pharmaceuticals Inc
Apexigen Inc
Aphios Corp
Apmonia Therapeutics SAS
Apogenix AG
Apollomics Inc
Applied Research using OMIC Sciences SL
Aprogen Inc
Apros Therapeutics Inc
Aptorum Group Ltd
Arbele Ltd
Argonaut Therapeutics Ltd
Arum Therapeutics Inc
Arvinas Inc
Asana BioSciences LLC
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Ascentawits Pharmaceuticals Ltd
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
AstraZeneca Plc
Atreca Inc
Aucentra Therapeutics Pty Ltd
Aulos Bioscience Inc
Aurigene Discovery Technologies Ltd
Avacta Life Sciences Ltd
Avesthagen Ltd
Avicenna Therapeutics Inc
B Cell Design SAS
Bantam Pharmaceutical LLC
Baobab AiBIO Co Ltd
Barricade Therapeutics Corp
Basilea Pharmaceutica Ltd
Bavarian Nordic AS
Bayer AG
BeiGene Ltd
Beijing BGI-GBI Biotech Co Ltd
Beijing Corregene Biotechnology Co Ltd
Beijing Eastern Biotech Co Ltd
Beijing Mabworks Biotech Co Ltd
Beijing Scitech-MQ Pharmaceuticals Ltd
Beijing Tricision Biotherapeutics Inc
Betta Pharmaceuticals Co Ltd
Bexion Pharmaceuticals LLC
Bicara Therapeutics Inc
Bicycle Therapeutics Plc
BIMINI Biotech BV
Bio4t2 LLC
BioAtla Inc
Biocad
BioCurity Pharmaceuticals Inc
BioEclipse Therapeutics Inc
BioMed Valley Discoveries Inc
BioNTech SE
Biosceptre International Ltd
Biosion Inc
Biosplice Therapeutics Inc
BioSyngen Pte Ltd
Biotheus Inc
BioVaxys Technology Corp
Bioviz Technologies Pvt Ltd
BioXcel Therapeutics Inc
bitBiome Co Ltd
bluebird bio Inc
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Bold Therapeutics Inc
Bolt Biotherapeutics Inc
BreakBio Corp
BriaCell Therapeutics Corp
BridgeBio Pharma Inc
BrightGene Bio-Medical Technology Co Ltd
Bristol-Myers Squibb Co
Bromodomain Pharmaceuticals Inc
C4 Therapeutics Inc
C4X Discovery Holdings Plc
Calithera Biosciences Inc
Cancer Advances Inc
Cancer Therapeutics Laboratories Inc
Canget BioTekpharma LLC
Cantargia AB
Captor Therapeutics SA
Cardiff Oncology Inc
Carina Biotech Pty Ltd
Carna Biosciences Inc
CaroGen Corp
Carrick Therapeutics Ltd
CAS-Lamvac Biotech Co Ltd
Catalym GmbH
CCRP Therapeutics GmbH
Cell Biotech Co Ltd
Celldex Therapeutics Inc
Cellivery Therapeutics Inc
Cellix Bio Pvt Ltd
Cello Therapeutics Inc
Celsius Therapeutics Inc
Centrymed Pharmaceutical Inc
CheMedImmune Inc
Chengdu Huachuang Biotechnology Co Ltd
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimeric Therapeutics Ltd
Chimerix Inc
China Resources Pharmaceutical Group Ltd
Chiome Bioscience Inc
ChoDang Pharm Co Ltd
Chong Kun Dang Pharmaceutical Corporation
Chongqing Precision Biotech Co Ltd
Chugai Pharmaceutical Co Ltd
Cinkate Corp
Cloaked Therapeutics LLC
CNBX Pharmaceuticals Inc
COARE Biotechnology Inc
Codiak BioSciences Inc
Coherent Biopharma
Compass Therapeutics Inc
Compugen Ltd
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
CTCELLS Inc
Culnexin Therapeutics LLC
Cura Therapeutics LLC
Curamir Therapeutics Inc
Curegenix Inc
Cytocraft Bio-Tech Development Co Ltd
CytomX Therapeutics Inc
D3 Bio Inc
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals Inc
Deka Biosciences Inc
Delta-Fly Pharma Inc
Denovo Biopharma LLC
DevaCell Inc
Dicerna Pharmaceuticals Inc
Divide and Conquer Ltd
DNAtrix Inc
Dnatwo Inc
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
Ectin Research AB
Eden Biologics Inc
eFFECTOR Therapeutics Inc
Eisai Co Ltd
Elevation Oncology Inc
Eli Lilly and Co
Elicio Therapeutics Inc
Elixiron Immunotherapeutics Inc
Ella Therapeutics Ltd
Eloxx Pharmaceuticals Inc
Elpiscience Biopharma Ltd
Elucida Oncology Inc
Eluciderm Inc
Endeavor BioMedicines
Enhancedbio Inc
Ennaid Therapeutics LLC
Enterome Bioscience SA
EntreChem SL
Enzo Biochem Inc
Epizyme Inc
Eternity Bioscience Inc
Euclises Pharmaceuticals Inc
Eucure (Beijing) Biopharma Co Ltd
Eutilex Co Ltd
Evgen Pharma Plc
Evotec SE
Exelixis Inc
ExonanoRNA LLC
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
f5 Therapeutics Inc
FasT Biopharma Ltd
Fate Therapeutics Inc
Fecula Biotech Corp
Felicitex Therapeutics Inc
Fog Pharmaceuticals Inc
Formosa Pharmaceuticals Inc
Forte Biosciences Inc
Fujifilm Holdings Corp
Fusion Pharmaceuticals Inc
G-Cell Co Ltd
Gadeta BV
GAiA BioMedicine Inc
Gbiologics Inc
GeneCare Research Institute Co Ltd
Genentech USA Inc
Generos Biomedical Technology (Hangzhou) Co Ltd
GeneScience Pharmaceuticals Co Ltd
Genexine Inc
GenFleet Therapeutics (Shanghai) Inc
GenoImmune Therapeutics Biotechnology Co Ltd
GeoVax Labs Inc
Gilead Sciences Inc
GLG Pharma SA
GlycoNex Inc
Glycostem Therapeutics BV
Glycotope GmbH
Gnubiotics Sciences SA
GO Therapeutics Inc
Gradalis Inc
Grand Pharmaceutical Group Ltd
Gritstone Bio Inc
GSK plc
GT Biopharma Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Doublle Bioproduct Inc
Handok Inc
Hangzhou Bensheng Pharmaceutical Co Ltd
Hangzhou DAC Biotech Co Ltd
Hangzhou Neoantigen Therapeutics Co Ltd
Hangzhou Zenshine Pharmaceuticals Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
Harpoon Therapeutics Inc
HCW Biologics Inc
HebeCell Corp
HEC Pharma Co Ltd
Heidelberg Pharma AG
Helixmith Co Ltd
Hercules Pharmaceuticals BV
Hibercell Inc
Hillstream BioPharma Inc
Hookipa Pharma Inc
Huadao Shanghai Biomedical Co Ltd
Huahui Anjian (Beijing) Biotechnology Co Ltd
Hubro Therapeutics AS
Hummingbird Bioscience Pte Ltd
Hutchison MediPharma Ltd
iDD biotech SAS
Ideaya Biosciences Inc
Idera Pharmaceuticals Inc
IGM Biosciences Inc
Ikena Oncology Inc
IMGENEX India Pvt Ltd
Immix BioPharma Inc
Immodulon Therapeutics Ltd
Immune Biosolutions Inc
Immuneering Corp
ImmuneOncia Therapeutics LLC
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immunitas Therapeutics Inc
ImmunityBio Inc
Immuno Cure BioTech Ltd
Immunocore Holdings Plc
Immunogenesis Inc
Immunophotonics Inc
immunoSCAPE Pte Ltd
Immunotech Biopharm Ltd
Immvira Co Ltd
IMPACT Therapeutics Inc
Imugene Ltd
Imvax Inc
Incanthera Plc
Incyte Corp
Indaptus Therapeutics Inc
Indivumed GmbH
Infinity Pharmaceuticals Inc
Inhibrx Inc
InnoCare Pharma Ltd
InnoCure Therapeutics Inc
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
InProTher ApS
Inspirna Inc
Intensity Therapeutics Inc
InteRNA Technologies BV
Interprotein Corp
Intezyne Inc
Intra-Cellular Therapies Inc
Invectys SA
InventisBio Co Ltd
IO Biotech Inc
iOmx Therapeutics AG
Ionova Life Science Co Ltd
Iovance Biotherapeutics Inc
Ipsen SA
ISOThrive Inc
ISU ABXIS Co Ltd
Iterion Therapeutics Inc
Jacobio Pharmaceuticals Group Co Ltd
Jazz Pharmaceuticals Plc
JenKem Technology Co Ltd
Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Sinorda Biomedicine Co Ltd
Jiangxi Jemincare Group Co Ltd
Johnpro Biotech Inc
Johnson & Johnson
Joint Biosciences Ltd
JSR Life Sciences LLC
KAHR medical Ltd
Karus Therapeutics Ltd
Karyopharm Therapeutics Inc
KeViRX Inc
Keythera Pharmaceuticals Co Ltd
Kezar Life Sciences Inc
Kiadis Pharma NV
Kineta Inc
Kirilys Therapeutics Inc
KLUS Pharma Inc
Kymera Therapeutics Inc
L&L Biopharma Co Ltd
L.E.A.F. Pharmaceuticals LLC
LaNova Medicines Ltd
Lantern Pharma Inc
Lead Discovery Center GmbH
Leap Therapeutics Inc
LegoChem Biosciences Inc
Lepu Biopharma Co Ltd
Les Laboratoires Servier SAS
LIfT BioSciences Ltd
Liminatus Pharma LLC
Linnaeus Therapeutics Inc
Locus Biosciences Inc
Lokon Pharma AB
Lumosa Therapeutics Co Ltd
Luye Pharma Group Ltd
Lyell Immunopharma Inc
Lytix Biopharma AS
Mabpharm Ltd
MacroGenics Inc
MAIA Biotechnology Inc
Malachite Innovations Inc
Mantis Therapeutics BV
Marino Biotechnology Co Ltd
Maverick Therapeutics Inc
MD Healthcare Inc
MD2 Biosciences Inc
MdBioLab
MedAnnex Ltd
MedBiome Inc
Medesis Pharma SA
MediaPharma SRL
Medicenna Therapeutics Corp
MediciNova Inc
Medigen Biotechnology Corp
MEI Pharma Inc
Mekanistic Therapeutics LLC
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Merus NV
Metagone Biotech Inc
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Moderna Inc
Molecular Partners AG
Molecular Templates Inc
Mologen AG
Morphogenesis Inc
Multimmune GmbH
Multitude therapeutics Inc
Nanjing KAEDI Biotech Inc
NantBioScience Inc
Navire Pharma Inc
NEOGAP Therapeutics AB
New Beta Innovation Ltd
NewG Lab Pharma Inc
NEX-I Inc
NextCure Inc
NGM Biopharmaceuticals Inc
NH TherAguix SAS
Nimbus Therapeutics LLC
Nitto BioPharma Inc
Novartis AG
Nuvalent Inc
OBI Pharma Inc
Oblique Therapeutics AB
Oceanyx Pharmaceuticals Inc
Omideon Ltd
Oncoinvent AS
Oncology Research International Ltd
Oncomatryx Biopharma SL
Onconic Therapeutics Co Ltd
Onconova Therapeutics Inc
OncoOne Research & Development GmbH
Oncostellae SL
Oncotelic Therapeutics Inc
Oncovir Inc
OnKure Inc
Ono Pharmaceutical Co Ltd
Onxeo SA
Opna Bio SA
Orano Med LLC
Orion Biotechnology Canada Ltd
Orum Therapeutics Inc
Oxford BioTherapeutics Ltd
Oxford Drug Design Ltd
P&PMed Shanghai Biotechnology Co Ltd
Pacific Meniuoke Biopharmaceutical Company
Pact Pharma Inc
Pacylex Pharmaceuticals Inc
Palleon Pharmaceuticals Inc
Panbela Therapeutics Inc
Parasol Biotech Co Ltd
Pasithea Therapeutics Corp
PDS Biotechnology Corp
Penrose Therapeutix LLC
Peptomyc SL
Perseus Proteomics Inc
PersonGen BioTherapeutics (Suzhou) Co Ltd
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
Pharos iBio Co Ltd
Phi Pharma SA
Phio Pharmaceuticals Corp
Phision Therapeutics
Pieris Pharmaceuticals Inc
Pionyr Immunotherapeutics Inc
Plexxikon Inc
POINT Biopharma Global Inc
Polaris Pharmaceuticals Inc
Portage Biotech Inc
Poseida Therapeutics Inc
Potenza Therapeutics Inc
Precision Biologics Inc
Prescient Therapeutics Ltd
PRISM Pharma Co Ltd
Privo Technologies Inc
Promontory Therapeutics Inc
Propanc Biopharma Inc
Protheragen Inc
Provectus Biopharmaceuticals Inc
PsiOxus Therapeutics Ltd
Psivac Ltd
Pure Biologics SA
Purple Biotech Ltd
Qilu Pharmaceutical Co Ltd
QLSF Biotherapeutics Inc
Qu Biologics Inc
Quadriga BioSciences Inc
Qualigen Therapeutics Inc
R-Pharm
RadBio
Radiopharm Theranostics Ltd
Radiopharm Ventures LLC
RaQualia Pharma Inc
Recursion Pharmaceuticals Inc
RedHill Biopharma Ltd
Regeneron Pharmaceuticals Inc
Replimune Ltd
Res Nova Bio Inc
Resonant Therapeutics Inc
Reven Holdings Inc
Revere Pharmaceuticals Inc
Revolution Medicines Inc
RhemaStem SRLS
Rhizen Pharmaceuticals SA
Rizen (Suzhou) Biosciences Co Ltd
Roivant Sciences Inc
Rophibio Inc
Roquefort Therapeutics Plc
Ryvu Therapeutics SA
Sagimet Biosciences Inc
Salarius Pharmaceuticals Inc
Salix Pharmaceuticals Ltd
Samjin Pharm Co Ltd
Sanofi
Sapience Therapeutics Inc
Sareum Holdings Plc
Scancell Holdings Plc
Scandion Oncology AS
Schrodinger Inc
Score Pharma Inc
Seagen Inc
Secarna Pharmaceuticals GmbH & Co KG
Second Genome Inc
Secura Bio Inc
Senda Biosciences Inc
Senti Biosciences Inc
Seven and Eight Biopharmaceuticals Corp
Shandong Luye Pharmaceutical Co Ltd
Shanghai Bioray Laboratory Inc
Shanghai Cell Therapy Group Co
Shanghai De Novo Pharmatech Co Ltd
Shanghai Escugen Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Gefeimu Biomedical Technology Co Ltd
Shanghai GeneChem Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Haishi Biopharmaceutical Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Shanghai HyaMab Biotech Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Keqi Pharmaceutical Technology Co Ltd
Shanghai Sailun Biotechnology Co Ltd
Shanghai Xunhe Pharmaceutical Technology Co Ltd
Shanghai Yihao Biotechnology Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Fapon Biopharma Inc
Shijiazhuang Sagacity New Drug Development Co Ltd
Sichuan Huiyang Life Science and Technology Corp
Sichuan Kelun Pharmaceutical Co Ltd
SignalChem Lifesciences Corp
Sihuan Pharmaceutical Holdings Group Ltd
Simcere Pharmaceutical Group Ltd
Singh Biotechnology LLC
Sino Biopharmaceutical Ltd
SinoCelltech Group Ltd
SiNOPSEE Therapeutics Pte Ltd
siRNAgen Therapeutics Corp
Sirnaomics Ltd
SiVEC Biotechnologies LLC
SN BioScience
Sorrento Therapeutics Inc
Sosei Group Corp
SOTIO Biotech AS
Spago Nanomedical AB
SpringWorks Therapeutics Inc
ST Pharm Co Ltd
Starpharma Holdings Ltd
Statera Biopharma Inc
STC Biologics Inc
Stcube Inc
StemGen SpA
Stemirna Therapeutics Ltd
Stemsynergy Therapeutics Inc
Stingthera Inc
Sumitomo Dainippon Pharma Oncology, Inc
Sumitomo Pharma Co Ltd
SuviCa Inc
Suzhou Dingfu Target Biotechnology Co Ltd
Suzhou GenHouse Pharmaceutical Co Ltd
Suzhou Zanrong Pharmaceutical Technology Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Suzhou Zerun New Drug Research and Development Co Ltd
Syncromune Inc
Syndivia SAS
Syntekabio Inc
Syros Pharmaceuticals Inc
Systimmune Inc
Tagworks Pharmaceuticals BV
Taiho Oncology Inc
Taiho Pharmaceutical Co Ltd
Tailored Therapeutics LLC
Takeda Pharmaceutical Co Ltd
Targovax ASA
Tarrex Biopharma Ltd
Tarveda Therapeutics Inc
Tasly Pharmaceutical Group Co Ltd
TCR2 Therapeutics Inc
Teclison Ltd
Tempest Therapeutics Inc
Tengji (Xiamen) Biomedical Technology Co Ltd
Teon Therapeutics Inc
Tessa Therapeutics Ltd
Theolytics Ltd
TheraBioPharma Inc
Theratechnologies Inc
Theravectys SA
Tonix Pharmaceuticals Holding Corp
Topadur Pharma AG
Toray Industries Inc
Totus Medicines Inc
TRACON Pharmaceuticals Inc
Transgene SA
Triumvira Immunologics Inc
Turning Point Therapeutics Inc
Tvardi Therapeutics Inc
Tyme Inc
UBI Pharma Inc
UCB SA
United BioPharma Inc
UWELL Biopharma Inc
VasGene Therapeutics Inc
Vaxil Bio Therapeutics Ltd
Vaximm AG
Venn Therapeutics LLC
Verastem Inc
Vidac Pharma
Vincerx Pharma Inc
Virocure Inc
Vivacitas Oncology Inc
VREX Therapeutics Inc
VS Pharmtech Co Ltd
WellMarker Bio Co Ltd
Western Oncolytics Ltd (Inactive)
WntResearch AB
Wuhan YZY Biopharma Co Ltd
Xbrane Biopharma AB
XEME BioPharma Inc
Xencor Inc
Xiangxue Life Sciences
XuanZhu Biological Technology Co Ltd
Xynomic Pharmaceuticals Holdings Inc
Yangtze River Pharmaceutical Group
Yisheng Biopharma Co Ltd
Yukin Therapeutics SAS
Zelluna Immunotherapy AS
Zhejiang Teruisi Pharmaceutical Co Ltd
Zhejiang Yangshengtang Biotech Co Ltd
Zymeworks Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Colorectal Cancer pipeline products market?
The key targets in the Colorectal Cancer pipeline products market are Programmed Cell Death Protein 1, GTPase KRas, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Epidermal Growth Factor Receptor, Programmed Cell Death 1 Ligand 1, Vascular Endothelial Growth Factor Receptor 2, DNA Topoisomerase I, Cells Expressing Epidermal Growth Factor Receptor, Cytotoxic T Lymphocyte Protein 4, and Serine/Threonine Protein Kinase B Raf, among others.
-
What are the key mechanisms of action in the Colorectal Cancer pipeline products market?
The key mechanisms of action in the Colorectal Cancer pipeline products market are Programmed Cell Death Protein 1 Antagonist, GTPase KRas Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Programmed Cell Death 1 Ligand 1 Inhibitor, DNA Topoisomerase I Inhibitor, Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor, Serine/Threonine Protein Kinase B Raf Inhibitors, CD3 Agonist, Epidermal Growth Factor Receptor Antagonist, and Leukocyte Surface Antigen CD47 Inhibitor, among others.
-
What are the key routes of administration in the Colorectal Cancer pipeline products market?
The key routes of administration in the Colorectal Cancer pipeline products market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, intramuscular, intradermal, topical, and intraperitoneal, among others.
-
What are the key molecule types in the Colorectal Cancer pipeline products market?
The key molecule types in the Colorectal Cancer pipeline products market are small molecule, monoclonal antibody, gene-modified cell therapy, monoclonal antibody conjugated, fusion protein, cell therapy, oncolytic virus, subunit vaccine, biologic, and synthetic peptide, among others.
-
Which are the leading companies in the Colorectal Cancer pipeline products market?
A few of the leading companies in the Colorectal Cancer pipeline products market are Novartis AG, AstraZeneca Plc, Bristol-Myers Squibb Co, Merck & Co. Inc, Pfizer Inc, Boehringer Ingelheim International GmbH, CSPC Pharmaceutical Group Ltd, BeiGene Ltd, Jacobio Pharmaceuticals Group Co Ltd, and Johnson & Johnson.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Colorectal Cancer reports